The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Hill Visits Yield Key Bill Support; Plus Medicare, Biosimilar Wins

ACR Hill Visits Yield Key Bill Support; Plus Medicare, Biosimilar Wins

May 20, 2019 • By Angus Worthing, MD, FACP, FACR

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Greetings from Washington, D.C., where ACR leaders just held more than 100 meetings on Capitol Hill supporting reforms to step therapy and prior authorization, increased reimbursement for dual-energy X-ray absorptiometry (DXA), solutions to the rheumatology workforce shortage, and rheumatology-specific research at the Pentagon. We’re already hearing great news about our successes: Hours after our visit, Representatives Schakowski and Burgess introduced a bill to repay medical school loans for pediatric rheumatologists (and other specialists), to help solve a critical need for kids with arthritis. We also generated interest in the Senate to introduce a companion bill to the House’s Safe Step Act, which would allow our patients to be exempted from step therapy in cases where you predict the insurance-preferred drug will be ineffective, cause side effects or reduce adherence—or have another common sense reason.

You Might Also Like
  • ACR/ARHP Visits the Hill; Drug Pricing ‘Blueprint’ Revealed
  • ACR & NPF Highlight Medicare Access Challenges in Capitol Hill Briefing
  • Help the ACR Bring Its Message to the Hill
Also By This Author
  • A Farewell Message from Outgoing Government Affairs Committee Chair Angus Worthing, MD, FACR, FACP

Keep the momentum going by taking one minute right now to send a pre-written email to Congress. Visit the ACR website (for rheumatologists and rheumatology professionals) or simpletasks.org (patients and families). Your emails will help convince your elected leaders that our initiatives matter. And follow the fun at #Act4Arthritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

RheumPAC
For U.S. based ACR/ARP members, after you send those emails to Congress, do two more quick things: First, decide for yourself what it’s worth to your practice and your patients for the ACR to be fighting for us in Washington, D.C., and make an investment in RheumPAC. Last year, 4% of ACR/ARP members made that calculation about the value of advocacy and supported our bipartisan political action committee (PAC) on behalf of the other 96% of members. Imagine what we would be able to accomplish if that number increased to just 10%—per the ACR’s strategic plan goals.

Second, encourage your medical group, division or state society to support the new RheumPAC Advocacy Fund. What’s that, you say? It’s a fund that allows groups of rheumatologists to support advocacy. While only individuals can give to RheumPAC to support rheumatology champions in Congress, groups can now invest in the Advocacy Fund to defray administrative costs of fundraising, fly-ins and other expenses. Email [email protected] to find out more, or send a check to RheumPAC Advocacy Fund, 2200 Lake Blvd. NE, Atlanta, GA 30319.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A Medicare Win
On May 16, the ACR logged another victory for our patients who receive in-office medications through Medicare. You may remember the ACR strenuously objected last August to the Trump administration’s announcement allowing Medicare Advantage plans to force our patients through step therapy before getting in-office infusion or injection medicines. This week, although the plan remains in effect, Medicare heeded the ACR’s request to protect patients currently receiving therapies (grandfathering/grandmothering) from going through step therapy. Instead of looking back only 108 days to check if patients are currently taking a medicine, plans must look back 365 days, where they will find many of our patients being treated at less frequent intervals.

Pages: 1 2 3 | Single Page

Filed Under: American College of Rheumatology, Legislation & Advocacy, Meeting Reports Tagged With: 2019 fly-in, ACR Capitol Hill visit, Biosimilars, medical school loans, Medicare, Medicare Reimbursement, pharmacy benefit managers (PBMs), Safe Step Act of 2019 (H.R. 2279), step therapy reform legislation

You Might Also Like:
  • ACR/ARHP Visits the Hill; Drug Pricing ‘Blueprint’ Revealed
  • ACR & NPF Highlight Medicare Access Challenges in Capitol Hill Briefing
  • Help the ACR Bring Its Message to the Hill
  • Keeping the Pressure on Congress: ACR Opposes Medicare Payment Adjustment Plan, Executive Order

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)